This notion is supported by the recent report by Mariathasan et al., which showed tumors from aetozolizumab non-responsive patients had higher expression of TGFβ and its receptors and lacked CD8+ TILs in the tumor epithelial compartment [45]. This evidence concerns the gene TGFB1 and neoplasm.